Metformina + Vildagliptina Zentiva

Metformin Hydrochloride, the active ingredient in Metformina + Vildagliptina Zentiva, is a biguanide/DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients.

GNH USA supplies Metformina + Vildagliptina Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support global distribution. Customers benefit from reliable lead times, secure packaging, and responsive technical support throughout the supply chain.

Metformina + Vildagliptina is used in the treatment of type 2 diabetes mellitus, targeting hyperglycemia through complementary mechanisms.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Inadequate glycemic control on metformin alone: adds DPP‑4 inhibition to improve insulin secretion. - Combination therapy in adults: simplifies regimen and enhances adherence.

Metformina + Vildagliptina may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness

Serious or Rare Side Effects: - Lactic acidosis - Severe hypoglycemia - Pancreatitis - Allergic skin reactions (e.g., Stevens‑Johnson syndrome)

When prescribing Metformina + Vildagliptina, clinicians should consider several safety aspects.

- Renal function: assess creatinine clearance before initiating therapy. - Hepatic impairment: use with caution in patients with liver disease. - Lactic acidosis risk: discontinue if signs of metabolic acidosis appear. - Pregnancy and lactation: safety not established; avoid unless benefits outweigh risks. - Drug interactions: review concomitant medications for potential additive hypoglycaemic effect. - Store at ambient temperature: keep in original container, protect from moisture.

Metformina + Vildagliptina can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Iodinated contrast media: may precipitate metformin‑associated lactic acidosis. - Insulin or sulfonylureas: increased risk of hypoglycaemia. - Cimetidine: raises metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and potassium. - Loop or thiazide diuretics: may affect metformin renal clearance. - Beta‑blockers: may mask hypoglycaemia symptoms. - Rifampin: may reduce vildagliptin exposure.